Health Care
The Food and Drug Administration dealt out approvals and delays Thursday setting some health stocks awry.
The FDA requested more safety data before it would approve migraine treatment Trexima, sending Pozen Pharmaceuticals(POZN) plummeting. Pozen lost $7.53, or 43%, to $9.92. But positive phase III data launched Pharmion(PHRM) 58.5% on Thursday. The company's Vidaza for treatment of high-risk myelodysplastic syndromes (MDS) performed well against conventional care regimens (CCR) in the late-stage trial. Pharmion gained $14.42, to $39.06. Also, CryCor(CRYO) rose after the FDA granted it premarket approval for its Cardiac Cryoablation System for the treatment of right atrial flutter. The company, which specializes in medical devices to treat cardiac arrhythmias, said it wills ell the system in the U.S. in the next several months. CryCor said more than 200,000 patients per year in the U.S. are diagnosed with this condition. The stock rose 44 cents, or 10.5%, to $4.64. Watson Pharmaceuticals(WPI) said Thursday that CEO Allen Chao is retiring. Barr Pharmaceuticals'(BRL) Chief Operating Officer Paul Bisaro will replace him. The company also gave quarterly results Thursday, reporting adjusted earnings of $37.9 million, or 34 cents a share, compared to a net loss of $25.9 million, or 24 cents a share, in the year-ago quarter. Analysts surveyed by Thomson Financial expected the company to earn 27 cents a share. Watson's shares were up $1.34, or 4.4%, at $31.69, and Barr edged 66 cents, or 1.3%, higher to $52.43.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,393.45 | 1,310.33 | 2,827.34 | 15.81 |
Oil *
101.78
|
|
DOWN
26.41 |
DOWN
2.99 |
DOWN
10.02 |
DOWN
0.44 |
10 Yr
1.58%
SPDR Gold
151.62
|
|
-0.21%
|
-0.23%
|
-0.35%
|
-2.71%
|
Data delayed 20 minutes |


Connect with TheStreet